Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
出版年份 2013 全文链接
标题
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 24, Issue 5, Pages 1267-1273
出版商
Oxford University Press (OUP)
发表日期
2013-01-05
DOI
10.1093/annonc/mds620
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
- (2015) Susan D. Richman et al. Analytical Cellular Pathology
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- (2012) D. Santini et al. ANNALS OF ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Detecting biomarkers with microdroplet technology
- (2012) Valérie Taly et al. TRENDS IN MOLECULAR MEDICINE
- KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
- (2011) H Bando et al. BRITISH JOURNAL OF CANCER
- Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
- (2011) S Weidlich et al. BRITISH JOURNAL OF CANCER
- Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer
- (2011) Fotios Loupakis et al. CANCER
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- Should Oncologists Be Aware in Their Clinical Practice ofKRASMolecular Analysis?
- (2011) Daniele Santini et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review
- (2011) J. M. Baas et al. ONCOLOGIST
- Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
- (2010) Li-Chen Yen et al. ANNALS OF SURGERY
- KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
- (2010) Magnus Sundström et al. BMC CANCER
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection
- (2010) Salih Ibrahem et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Biased Discordance of KRAS Mutation Detection in Archived Colorectal Cancer Specimens Between the ARMS-Scorpion Method and Direct Sequencing
- (2010) H. Bando et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- (2009) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients
- (2009) Byeong Seok Sohn et al. ONCOLOGY
- Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
- (2009) Vassiliki Kotoula et al. PLoS One
- Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer
- (2008) Salvatore Artale et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started